Exact Sciences to Use MDxHealth Methylation Biomarker, PCR Tech in Cologuard Test | GenomeWeb

MDxHealth said this week that Exact Sciences will use MDxHealth's methylation biomarker and methylation-specific PCR technology in Cologuard, Exact's non-invasive, stool-based DNA colon cancer screening test currently under development.

Exact Sciences licensed several methylation biomarkers, among other biomarkers, and the PCR technology in July, before MDxHealth changed its name from OncoMethylome. Exact has been evaluating the technologies since that time, in studies with Cologuard.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.